In today’s recent session, 2.26 million shares of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) have been traded, and its beta is 0.87. Most recently the company’s share price was $9.39, and it changed around $0.54 or 6.10% from the last close, which brings the market valuation of the company to $2.23B. RXRX at last check was trading at a discount to its 52-week high of $16.75, offering almost -78.38% off that amount. The share price’s 52-week low was $4.97, which indicates that the recent value has risen by an impressive 47.07% since then. We note from Recursion Pharmaceuticals Inc’s average daily trading volume that its 3-month average coming to 4.64 million.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX has been showing a green trend so far today with a performance of 6.10% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently down -4.77% year-to-date, but still up 1.40% over the last five days. On the other hand, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is 0.32% up in the 30-day period.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Recursion Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -0.74 percent over the past six months and at a -1.27% annual growth rate that is well below the industry average of 13.30%. The year-over-year growth rate is expected to be 32.20%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 13.75M in revenue for the current quarter. 6 analysts expect Recursion Pharmaceuticals Inc to make 13.93M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 11.02M and 10.53M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 24.80%. Forecasts for the next quarter put sales growth at 32.30%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -43.41%. Recursion Pharmaceuticals Inc earnings are expected to increase by -5.93% in 2024, but the outlook is positive 12.00% per year for the next five years.
RXRX Dividends
Recursion Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in July.
